FDA
-
-
-
-
-
-
-
Azitra receives US patent for ATR-12 Netherton syndrome treatment
-
-
-
-
-
-
-
Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders
-
-
-
-
-
-
-
Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates
-
-
-
-
-
-
-
Azitra Receives Notice of Non-Compliance from NYSE American
-
-
-
-
-
-
-
Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome
-
-
-
-
-
-
-
Azitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical Pipeline
-
-
-
-
-
-
-
Azitra, Inc (AZTR) Prices 4.86M Share Offering at $0.30/sh
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

